Skip to main content

Table 1 Clinical characteristics of the patients with axial spondyloarthritis and healthy controls

From: S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity

  nr-axSpA (n = 21)AS I (n = 17)AS II (n = 20)Healthy controls
(n = 40)
Age (years)median [IQR]30.6 [28.6–40.7]31.6 [27.2–37.3]37.3 [32.6–40.8]34.3 [30.1–38.6]
Sex (male gender)N (%)11 (52)15 (88)16 (80)31 (72)
Disease durationa
(years)
median [IQR]0.1 [0.0–5.0]3.0 [0.7–6.0]4.7 [3.8–9.0]
BASDAI (units NRS)median [IQR]4.8 [1.6–5.7]7.1 [4.4–8.0]4.5 [2.7–5.7]
HLA-B27 (+)N (%)21 (100)14 (82)16 (80)
CRP, mg/Lmedian [IQR]3.2 [2.4–5.2]6.4 [5.4–7.3]4.5 [3.6–5.1]
Uveitis (+)N (%)9 (43)6 (35)8 (40)
Psoriasis (+)N (%)0 (0)0 (0)0 (0)
Enthesitis (+)N (%)13 (62)1 (6)7 (35)
IBD (+)N (%)1 (5)0 (0)0 (0)
Peripheral arthritis (+)N (%)18 (86)10 (59)15 (75)
NSAIDsN (%)15 (71)13 (77)9 (45)
csDMARDsN (%)6 (29)3 (18)0 (0)
TNF inhibitorsN (%)0 (0)1 (6)11 (55)
  1. nr-axSpA Non-radiographic axial spondyloarthritis, AS I Ankylosing spondylitis without spinal involvement, AS II Ankylosing spondylitis with the presence of syndesmophytes, BASDAI The Bath Ankylosing Spondylitis Disease Activity Index, NRS Numeric Rating Scale, csDMARDs Conventional synthetic disease-modifying antirheumatic drugs, CRP C-reactive protein, IBD Inflammatory bowel disease, IQR Interquartile range, N Number of individuals, NSAIDs Non-steroidal anti-inflammatory drugs, TNF Tumor necrosis factor
  2. asince diagnosis